<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
<channel>
<title>Pharmaceutical  Drug Views - Medical Information Health Drugs Conditions Pharmacy Pills</title>
<description>medicinal, drug, pill, pharmacy, generic, prescription, preparing, use, overdose, warnings, precautions, storage, side effects, Drug Views, drugs, Medical, Information, Health, Drugs, Conditions, Pharmacy, Pills</description>
<link>http://www.drugviews.com/articles.php</link>
<language>en-us</language>
<generator>Ateom.com - Website Power Tools</generator>

<item>
<title>SaveRxCanada.com announces enhancement to online shopping system</title>
<description><![CDATA[SaveRxCanada.com, the premier Canadian pharmacy intermediary since 2004, announced an enhancement to its full <A HREF='http://www.pricerx.org/'>online</A> shopping system.]]></description>
<pubDate>Thu, 02 Sep 2010 08:56:00 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=SaveRxCanada-com-announces-enhancement-to-online-shopping-system</link>
</item>

<item>
<title>iBio and CMB enter development and marketing collaboration with GE Healthcare</title>
<description><![CDATA[iBio, Inc., its development collaborator, Fraunhofer USA Center for Molecular Biotechnology (CMB), and GE Healthcare, a unit of General Electric Company, today announced their entry into an agreement to jointly develop and globally market manufacturing solutions for biopharmaceuticals and vaccines based upon their respective proprietary technologies.]]></description>
<pubDate>Thu, 02 Sep 2010 08:29:00 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=iBio-and-CMB-enter-development-and-marketing-collaboration-with-GE-Healthcare</link>
</item>

<item>
<title>Dietary supplement combining zinc, phytase enhances effectiveness of BTX injections: Study</title>
<description><![CDATA[<A HREF='http://www.healthcare-opportunity.com/'>Taking a</A> dietary supplement of organic zinc and the enzyme phytase four days before receiving botulinum toxin injections made the toxin <A HREF='http://www.superdiscountprescriptions.com/'>more</A> effective in 93 percent of patients <A HREF='http://www.approvedpillsource.com/'>tested</A> in a recent study at The Methodist Hospital in Houston.]]></description>
<pubDate>Thu, 02 Sep 2010 07:52:00 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=Dietary-supplement-combining-zinc-phytase-enhances-effectiveness-of-BTX-injections-Study</link>
</item>

<item>
<title>Researchers develop new technique to trace counterfeit drugs</title>
<description><![CDATA[Counterfeiting of drugs is a huge industry with an annual turnover of more than SEK 500 billion. In Africa the situation is extremely serious. Half of the malaria medication sold there could be ineffective or even harmful. Researchers from Lund and the UK have now developed a technique that could resolve the situation.]]></description>
<pubDate>Thu, 02 Sep 2010 07:29:49 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=Researchers-develop-new-technique-to-trace-counterfeit-drugs</link>
</item>

<item>
<title>pSivida announces FDA Priority Review status for Iluvien NDA</title>
<description><![CDATA[pSivida Corp., a leader in the development of sustained release back of the eye <A HREF='http://www.drug-doctor.com/'>drug</A> delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has been notified that the U.S. Food and Drug Administration (FDA) has granted Priority Review status for the New Drug Application (NDA) filed for Iluvien for the treatment diabetic macular edema (DME).]]></description>
<pubDate>Tue, 31 Aug 2010 09:20:17 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=pSivida-announces-FDA-Priority-Review-status-for-Iluvien-NDA</link>
</item>

<item>
<title>Pharmacists on Health Care Teams Significantly Improve Patient Care</title>
<description><![CDATA[Inc]]></description>
<pubDate>Mon, 30 Aug 2010 00:00:00 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=Pharmacists-on-Health-Care-Teams-Significantly-Improve-Patient-Care</link>
</item>

<item>
<title>New alchemy module allows healthcare providers to verify, comply with state and federal prescription drug regulations</title>
<description><![CDATA[Gold Standard/Elsevier, developer of <A HREF='http://www.drugpharmacist.com/'>drug</A> databases and medication management solutions, announced today the availability of its new Alchemy.]]></description>
<pubDate>Fri, 27 Aug 2010 09:56:00 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=New-alchemy-module-allows-healthcare-providers-to-verify-comply-with-state-and-federal-prescription-drug-regulations</link>
</item>

<item>
<title>Ricerca Biosciences completes purification of an API under cGMP controls</title>
<description><![CDATA[Ricerca Biosciences, a uniquely integrated preclinical contract research <A HREF='http://www.druginformations.org/'>organization</A> (CRO) providing services to the biopharmaceutical industry, is pleased to announce the successful completion of the purification of an active <A HREF='http://www.pharmaceutical-sale.com/'>pharmaceutical</A> ingredient (API) under current <A HREF='http://www.happyrxbuy.com/'>good</A> manufacturing practices (cGMP) controls.]]></description>
<pubDate>Fri, 27 Aug 2010 05:51:20 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=Ricerca-Biosciences-completes-purification-of-an-API-under-cGMP-controls</link>
</item>

<item>
<title>SYSPRO ERP solution support pharmaceutical manufacturers to new FDA regulation</title>
<description><![CDATA[SYSPRO, the leading provider of visionary, pragmatic ERP software, today announced that the company is highly confident that the SYSPRO ERP solution will enable pharmaceutical manufacturers to meet the new U.S. Food and Drug Administration (FDA) regulations being proposed by Congress.]]></description>
<pubDate>Fri, 27 Aug 2010 02:23:54 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=SYSPRO-ERP-solution-support-pharmaceutical-manufacturers-to-new-FDA-regulation</link>
</item>

<item>
<title>Kent Elected ASHP President</title>
<description><![CDATA[Sta]]></description>
<pubDate>Fri, 27 Aug 2010 00:00:00 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=Kent-Elected-ASHP-President</link>
</item>

<item>
<title>Publix Super Markets to introduce flu immunization program</title>
<description><![CDATA["Flu clinics are an extension of the services our pharmacies provide to our customers as a convenient and <A HREF='http://www.pricerx.org/'>affordable</A> way to receive their vaccinations," said Maria Brous, Publix director of media and community relations. "At Publix, our pharmacies are dedicated to building relationships with our customers and their families for total <A HREF='http://www.hearbalhealth4u.com/'>health</A> and wellness all year long."]]></description>
<pubDate>Mon, 23 Aug 2010 12:19:19 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=Publix-Super-Markets-to-introduce-flu-immunization-program</link>
</item>

<item>
<title>Impax confirms initiation of challenge of patents listed by MSP Singapore for VYTORIN</title>
<description><![CDATA[Impax Laboratories, Inc. today confirms that it has initiated a challenge of patents listed by MSP Singapore Co. LLC in connection with VYTORIN® (ezetimibe/simvastatin), 10 <A HREF='http://www.fioricet40mg.com/'>mg</A>/80 <A HREF='http://www.fioricet40mg.com/'>mg</A>.]]></description>
<pubDate>Sat, 21 Aug 2010 03:04:55 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=Impax-confirms-initiation-of-challenge-of-patents-listed-by-MSP-Singapore-for-VYTORIN</link>
</item>

<item>
<title>Combination of 2 FDA approved drugs eliminate HIV infection</title>
<description><![CDATA[Researchers at the University of Minnesota Academic Health Center have identified two <A HREF='http://www.ultrarxdrugs.com/'>drugs</A> that, when combined, may serve as an effective treatment for HIV.]]></description>
<pubDate>Sat, 21 Aug 2010 01:59:11 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=Combination-of-2-FDA-approved-drugs-eliminate-HIV-infection</link>
</item>

<item>
<title>USPTO to allow patent for Advaxis’s new vaccine technology</title>
<description><![CDATA[Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has been notified that the US Patent and Trademark Office (USPTO) will allow a patent issuance of its application No. 11/785,249 entitled "Antibiotic Resistance Free Vaccines and Methods for Constructing and Using Same."]]></description>
<pubDate>Sat, 21 Aug 2010 01:50:45 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=USPTO-to-allow-patent-for-Advaxis-s-new-vaccine-technology</link>
</item>

<item>
<title>Carbidopa-Levodopa-Entacapone Therapy May Increase Risk of Cardiovascular Events</title>
<description><![CDATA[<A HREF='http://www.rxmedicare.org/'>FDA</A> announced today that an agency-conducted meta-analysis found a small increased risk of myocardial infarction, stroke, and cardiovascular-related death in patients who received carbidopa&#8211;levodopa&#8211;entacapone therapy instead of the standard <A HREF='http://www.drugs-to-go.com/'>combination</A> of carbidopa and levodopa.
But that finding, the agency noted, did not hold up when data from one <A HREF='http://www.drug-care.info/'>study</A> were eliminated from the 15-<A HREF='http://www.drug-care.info/'>study</A> meta-analysis.]]></description>
<pubDate>Fri, 20 Aug 2010 00:00:00 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=Carbidopa-Levodopa-Entacapone-Therapy-May-Increase-Risk-of-Cardiovascular-Events</link>
</item>

<item>
<title>Stakeholders Urge Overhaul of REMS Programs</title>
<description><![CDATA[<A HREF='http://www.drugpharmacist.com/'>FDA</A> officials in July engaged with dozens of stakeholders, including pharmacists, who want to ease the burden placed on the <A HREF='http://www.healthfitnessportal.com/'>health</A> <A HREF='http://www.medicare-california.com/'>care</A> system by risk evaluation and mitigation strategy (REMS) programs for medications.]]></description>
<pubDate>Tue, 17 Aug 2010 00:00:00 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=Stakeholders-Urge-Overhaul-of-REMS-Programs</link>
</item>

<item>
<title>Amphetamine abuse associated with increased risk of aortic dissection</title>
<description><![CDATA[<A HREF='http://www.modelsromania.com/'>Young</A> adults who abuse amphetamines may be at <A HREF='http://www.morerx.info/'>greater</A> risk of suffering a tear in the main artery leading from the heart, UT Southwestern Medical Center researchers have found.]]></description>
<pubDate>Mon, 16 Aug 2010 12:33:01 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=Amphetamine-abuse-associated-with-increased-risk-of-aortic-dissection</link>
</item>

<item>
<title>CVS/Pharmacy opens new store in Omaha</title>
<description><![CDATA[CVS/<A HREF='http://www.low-cholesterol-pharmacy.com/'>pharmacy</A> celebrated its entry into the Omaha market today with a grand opening at one of its two new stores in the city of Omaha.  Joining CVS officials at the ceremony were The Honorable Jim Suttle, Mayor of Omaha and City Councilmember Thomas Mulligan, District #7.]]></description>
<pubDate>Mon, 16 Aug 2010 12:29:04 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=CVS-Pharmacy-opens-new-store-in-Omaha</link>
</item>

<item>
<title>Jiangbo receives Shandong FDA approval to market Felodipine SR tablets</title>
<description><![CDATA[Jiangbo Pharmaceuticals, Inc., today announced that the Company received approval from the Shandong Food and Drug Administration to start the sales of Felodipine sustained release tablets.]]></description>
<pubDate>Mon, 16 Aug 2010 10:12:02 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=Jiangbo-receives-Shandong-FDA-approval-to-market-Felodipine-SR-tablets</link>
</item>

<item>
<title>Cangene to focus commercialization efforts on key markets</title>
<description><![CDATA[Cangene Corporation today reports that it will further focus its commercialization efforts on key markets for its <A HREF='http://www.rxpillsguide.com/'>products</A> in the near term. Cangene acquired the U.S. commercialization rights to HepaGam B(R) (Hepatitis B Immune Globulin Intravenous (Human)) in October 2009 and soon after began building a U.S. <A HREF='http://www.pharmacysalesonline.com/'>sales</A> force.]]></description>
<pubDate>Mon, 16 Aug 2010 06:53:25 -0400</pubDate>
<link>http://www.drugviews.com/articles.php?t=Cangene-to-focus-commercialization-efforts-on-key-markets</link>
</item>

</channel>
</rss>